Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: A pilot study of the Southeastern Cancer Study Group

J. D. Hainsworth, L. L. Porter, D. H. Johnson, K. R. Hande, S. N. Wolff, R. Birch, G. Enas, F. A. Greco

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Ninety-two patients with advanced non-small cell lung cancer were treated with a combination chemotherapy regimen containing cisplatin, vindesine, and etoposide. Eighteen patients (20%) achieved major responses to therapy (three complete responders and 15 partial responders). Response rates were similar in each histologic subtype. Initial performance status was an important determinant of response; 42% of the patients with a Karnofsky performance status ≥70% responded versus 5% of those with a performance status <50%. The median duration of partial response was 21 weeks; complete responders had a median response duration of 50 weeks. The median survival for the entire group was 23.5 weeks. Toxicity with this regimen was acceptable; myelosuppression was the major toxic effect and was severe in only 10% of the patients. This regimen produced response rates comparable to those reported with other combinations containing cisplatin. Survival advantage in patients receiving this treatment is not established.

Original languageEnglish (US)
Pages (from-to)339-341
Number of pages3
JournalCancer treatment reports
Volume70
Issue number3
StatePublished - Jun 18 1986

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hainsworth, J. D., Porter, L. L., Johnson, D. H., Hande, K. R., Wolff, S. N., Birch, R., Enas, G., & Greco, F. A. (1986). Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: A pilot study of the Southeastern Cancer Study Group. Cancer treatment reports, 70(3), 339-341.